Patent · US Active

Tetrahydropyrazolopyrimidine compounds

US10640500B2 · kind B2 · utility

1Cited by

7References

5Claims

0Family size

Assignee

Eisai R&D Management Co., Ltd. · JP

Inventors

Roch Boivin · North Chelmsford, US
Eric Carlson · Merrimack, US
Atsushi Endo · Boston, US
Hans Hansen · Somerville, US
Lynn Hawkins · Concord, US
Sally Ishizaka · Weston, US
Matthew Mackey · Melrose, US
Sridhar Narayan · Belmont, US
Takashi Satoh · Andover, US
Shawn Schiller · Haverhill, US

Key dates

Filing date	Dec 14, 2017
Grant date	May 5, 2020
Priority date	—
Expiry date	Dec 14, 2037

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02P20/582
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.